Short answer
TuHURA Biosciences, Inc./NV (HURA) filed an 8-K current report with the SEC on August 19, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 5.07 (Submission of Matters to a Vote of Security Holders). $50 million revolving credit facility from Parkview, providing TuHURA with additional liquidity.
TuHURA Biosciences, Inc./NV 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- $50 million revolving credit facility from Parkview, providing TuHURA with additional liquidity
- 1,878,287 common shares committed to Parkview as loan-fee consideration
- Loan-fee shares remain subject to stockholder approval, creating potential dilution if authorized
- Equity issuance links financing costs to shareholder approval and future share countաճ
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Six director nominees elected to serve through the 2027 annual meeting, with 43,034,024 shares represented
- Nasdaq approval authorizes issuance of 1,878,287 common shares under the Fee Letter, creating potential dilution
- Executive compensation approved on an advisory basis, with 26,125,280 votes for and 2,484,951 against
- Three-year frequency selected for future executive compensation votes
- Cherry Bekaert LLP ratified as independent auditor for fiscal year ending December 31, 2026, with 42,911,888 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TuHURA Biosciences, Inc./NV 8-K filings
Get the next HURA 8-K as it lands
Follow HURA for push alerts, or ask the research agent what this filing means.